A Study of Rocbrutinib in Combination With Lacutoclax in Patients With B-Cell Malignancies
A phase 1/2 trial of Rocbrutinib in mantle cell lymphoma and diffuse large b-cell lymphoma, run by Guangzhou Lupeng Pharmaceutical Company LTD., now recruiting.
Overview
A Study of Rocbrutinib in Combination With Lacutoclax in Patients With B-Cell Malignancies is a phase 1/2 interventional study registered as NCT07609862 by Guangzhou Lupeng Pharmaceutical Company LTD., with 92 participants planned, started 2026-07-14 and due to reach its primary completion in 2029-06-30. Interventions recorded: Lacutoclax+Rocbrutinib. Conditions listed: Mantle Cell Lymphoma (MCL), Diffuse Large B-Cell Lymphoma (DLBCL), Follicular Lymphoma ( FL), Waldenström Macroglobulinemia (WM). No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialA Study of Rocbrutinib in Participants With Relapse or Refractory Mantle Cell Lymphoma
Shares Rocbrutinib, Mantle cell lymphoma.
- TrialA Study of Rocbrutinib Versus Investigator's Choice of BTK Inhibitors in Patients With Relapsed or Refractory Mantle Cell Lymphoma
Shares Rocbrutinib, Mantle cell lymphoma.
- PersonYuqin Song
Shares Mantle cell lymphoma, Follicular lymphoma, Diffuse large B-cell lymphoma.
- TrialA Long-term Extension Study of PCI-32765 (Ibrutinib)
Shares Mantle cell lymphoma, Follicular lymphoma, Diffuse large B-cell lymphoma.
- TrialGene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
Shares Mantle cell lymphoma, Follicular lymphoma, Diffuse large B-cell lymphoma.
- TrialA Study of Nemtabrutinib (MK-1026) in Participants With Relapsed or Refractory Hematologic Malignancies (ARQ 531-101/MK-1026-001)
Shares Mantle cell lymphoma, Follicular lymphoma, Diffuse large B-cell lymphoma.
- TrialPhase 1/2 Study of CD19 Chimeric Antigen Receptor T-cell (CD19 CAR-T; PL001) for Relapsed or Refractory B-cell Lymphoma
- TermLugano classification / Ann Arbor staging
Shares Mantle cell lymphoma, Follicular lymphoma, Diffuse large B-cell lymphoma.